Similar articles

• Evidence supports blind screening for internal malignancy in dermatomyositis: Data from 2 large US dermatology cohorts.

  Leatham H, Schadt C, Chisolm S, Fretwell D, Chung L, Callen JP, Fiorentino D. Leatham H, et al. Medicine (Baltimore). 2018 Jan;97(2):e9639. doi: 10.1097/MD.0000000000009639. Medicine (Baltimore). 2018. PMID: 29480875 Free PMC article.
• Serum CA-125 screening for ovarian cancer in patients with dermatomyositis.

  Whitmore SE, Anhalt GJ, Provost TT, Zacur HA, Hamper UM, Helzlsouer KJ, Rosenshein NB. Whitmore SE, et al. Gynecol Oncol. 1997 May;65(2):241-4. doi: 10.1006/gyno.1997.4666. Gynecol Oncol. 1997. PMID: 9159332 Clinical Trial.
• Dermatomyositis and malignancy: should all patients with dermatomyositis undergo malignancy screening?

  Khanna U, Galimberti F, Li Y, Fernandez AP. Khanna U, et al. Ann Transl Med. 2021 Mar;9(5):432. doi: 10.21037/atm-20-5215. Ann Transl Med. 2021. PMID: 33842653 Free PMC article. Review.
• Paraneoplastic Dermatomyositis in a Patient with Metastatic Gastric Carcinoma.

  Pozharashka J, Dourmishev L, Rusinova D, Balabanova M, Miteva L. Pozharashka J, et al. Acta Dermatovenerol Croat. 2020 Aug;28(2):120-122. Acta Dermatovenerol Croat. 2020. PMID: 32876041
• Autoantibodies and Cancer Association: the Case of Systemic Sclerosis and Dermatomyositis.

  Fiorentino DF, Casciola-Rosen L. Fiorentino DF, et al. Clin Rev Allergy Immunol. 2022 Dec;63(3):330-341. doi: 10.1007/s12016-022-08944-y. Epub 2022 May 20. Clin Rev Allergy Immunol. 2022. PMID: 35593962 Free PMC article. Review.